GRACEcast
Oncology experts summarize current and emerging issues in cancer management for patients and caregivers. Information from the Global Resource for Advancing Cancer Education (GRACE) helps people to become informed partners in their care.
Visit Show Website http://cancerGRACE.org/Recently Aired
-
HD
Doctors Discuss: Immunotherapy in Lung Cancer
Dr. Jack West, Dr. Julie Brahmer, and Dr. Ben Creelan ...
Dr. Jack West, Dr. Julie Brahmer, and Dr. Ben Creelan discuss the excitement the medical community is feeling about immunotherapy for the treatment of lung cancer. February 2014
-
HD
Understanding Acquired Resistance in ALK+ Lung Cancer
Dr. Robert Doebele explains why he feels that repeat biopsies ...
Dr. Robert Doebele explains why he feels that repeat biopsies help researchers better understand why ALK+ lung cancer patients become resistant to current treatments - and why some do better than expected. February 2014
-
HD
Treating Brain Mets in ALK+ Lung Cancer
For ALK+ lung cancer patients, brain metastases are a common ...
For ALK+ lung cancer patients, brain metastases are a common concern. Dr. Robert Doebele discusses the options available to treat brain mets as well as drugs that may break through the blood/brain barrier. February 2014
-
HD
Are EGFR TKIs (Such as Tarceva) Effective in Lung Cancer Patients Who Are Wild Type EGFR?
For patients with wild type EGFR, meaning there is no ...
For patients with wild type EGFR, meaning there is no EGFR mutation, drugs like Tarceva (erlotinib) can have a small benefit, but Dr. Joan Schiller wants research to do better. February 2014
-
HD
Sym-004 Offers Hope for EGFR Wild Type Lung Cancer Patients
Eighty percent of lung cancer patients have wild type EGFR, ...
Eighty percent of lung cancer patients have wild type EGFR, meaning there is no EGFR mutation. Dr. Joan Schiller of UT Southwestern Medical Center discusses a new drug in development that may help those patients. February 2014
-
HD
It's Time to Get Over the Lung Cancer Stigma
The stigma of lung cancer can lead to shame, fear, ...
The stigma of lung cancer can lead to shame, fear, and sub-optimal care. Dr. Joan Schiller wants us all to get past it, and she's leading the charge to make that happen. February 2014.
-
HD
Molecular Testing in Early Stage Non-Small Cell Lung Cancer
Does it make sense to do molecular testing on early ...
Does it make sense to do molecular testing on early stage lung cancer patients? Dr. Taofeek Owonikoko of Emory University School of Medicine and the Winship Cancer Institute thinks it does in some settings. February 2014
-
HD
Targeted Therapies for Stage III Non-Small Cell Lung Cancer
Will the success seen for stage IV patients receiving targeted ...
Will the success seen for stage IV patients receiving targeted therapies translate into cure for stage III patients? Dr. Daniel Morgensztern of the Washington University School of Medicine talks about what research is ongoing to answer that question.
-
HD
Small Cell Lung Cancer Clinical Trial: Is ECOG 2511 Right for You?
A current clinical trial (as of May 2014) asks if ...
A current clinical trial (as of May 2014) asks if adding veliparib to chemo will increase progression free surival for late stage small cell lung cancer patients. For more information, visit clinicaltrials.gov and enter "ECOG 2511" in the search box.
-
HD
I'm Very Optimistic. For the First Time.
Thanks to research, Dr. Daniel Morgensztern of the Washington University ...
Thanks to research, Dr. Daniel Morgensztern of the Washington University School of Medicine sees reason to be hopeful in the fight against lung cancer. February 2014
